Literature DB >> 20403350

Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature.

Elisa Prieto-Lara1, Aurora Llanos-Méndez.   

Abstract

A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8 microg) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20403350     DOI： 10.1016/j.vaccine.2010.03.068

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  13 in total

1.  Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Authors:  Jeremy C Jones; Erik W Settles; Curtis R Brandt; Stacey Schultz-Cherry
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Authors:  Abylay R Sansyzbay; Marianna K Erofeeva; Berik M Khairullin; Nurlan T Sandybayev; Zhailaubay K Kydyrbayev; Seidigapbar M Mamadaliyev; Markhabat M Kassenov; Maria V Sergeeva; Julia R Romanova; Vera Z Krivitskaya; Oleg I Kiselev; Marina A Stukova
Journal:  Clin Vaccine Immunol       Date:  2013-06-26

Review 3.  Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

Authors:  Andrew J Broadbent; Kanta Subbarao
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

4.  Nizatidine, a small molecular compound, enhances killed H5N1 vaccine cell-mediated responses and protects mice from lethal viral challenge.

Authors:  Shuang Wang; Bing Wu; Jia Xue; Ming Wang; Ruiai Chen; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2013-11-19       Impact factor: 3.452

5.  A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.

Authors:  Feng Liu; Xiangjie Sun; Jeffery Fairman; David B Lewis; Jacqueline M Katz; Min Levine; Terrence M Tumpey; Xiuhua Lu
Journal:  Virology       Date:  2016-03-21       Impact factor: 3.616

6.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970

Review 7.  Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses.

Authors:  Lamberto Manzoli; John P A Ioannidis; Maria Elena Flacco; Corrado De Vito; Paolo Villari
Journal:  Hum Vaccin Immunother       Date:  2012-07-01       Impact factor: 3.452

8.  Memory immune responses against pandemic (H1N1) 2009 influenza virus induced by a whole particle vaccine in cynomolgus monkeys carrying Mafa-A1*052:02.

Authors:  Masahiko Arikata; Yasushi Itoh; Masatoshi Okamatsu; Toshinaga Maeda; Takashi Shiina; Keiko Tanaka; Shingo Suzuki; Misako Nakayama; Yoshihiro Sakoda; Hirohito Ishigaki; Ayato Takada; Hideaki Ishida; Kosuke Soda; Van Loi Pham; Hideaki Tsuchiya; Shinichiro Nakamura; Ryuzo Torii; Takeshi Shimizu; Hidetoshi Inoko; Iwao Ohkubo; Hiroshi Kida; Kazumasa Ogasawara
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

Review 9.  Influenza vaccination in the elderly: why are the overall benefits still hotly debated?

Authors:  C Trucchi; C Paganino; A Orsi; D De Florentiis; F Ansaldi
Journal:  J Prev Med Hyg       Date:  2015-06-10

10.  Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.

Authors:  Gabriel Pedersen; Diane Major; Sarah Roseby; John Wood; Abdullah S Madhun; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-05-09       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.